Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Olanzapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 7/20 | 0.95 |
| ▸ | HTR2A known ✓ | P28223 | 5/20 | 0.95 |
| ▸ | HTR2C known ✓ | P28335 | 5/20 | 0.95 |
| ▸ | DRD4 known ✓ | P21917 | 4/20 | 0.95 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.95 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 5/20 | 0.95 |
| ▸ | CHRM4 | P08173 | 5/20 | 0.95 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.95 |
| ▸ | CHRM3 | P20309 | 5/20 | 0.95 |
| ▸ | DRD1 | P21728 | 5/20 | 0.95 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.95 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.95 |
| ▸ | HRH1 | P35367 | 5/20 | 0.95 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.95 |
| ▸ | HTR2B | P41595 | 5/20 | 0.95 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.95 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.95 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.95 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Olanzapine SCHEMBL16114506 | 1.00 | CHRM1 (0.95) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1376031 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1634614 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL5091769 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1375329 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL1562676 | 0.99 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL4775632 | 0.98 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL28763 | 0.98 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL29358280 | 0.98 | CHRM1 (1.00) | CHRM1DRD2CHRM2CHRM4CHRM5 | |
| Olanzapine SCHEMBL2222724 | 0.97 | CHRM1 (0.98) | CHRM1DRD2CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137563-A1 | PROCESS FOR THE PREPARTION OF OLANZAPINE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-05-28 | — | — | US | claimed |
| EP-1997822-A1 | Process for the preparation of 2-methyl-4-(4-methylpiperazin-1-yl)-10h-thieno-[2,3-b] [1,5] benzodiazepine dihydrochloride trihydrate, 2-methyl-4-(4-methyl-piperazin-1-yl) -10h-thieno[2,3-b] [1,5] benzodiazepine dihydrochloride trihydrate, pharmaceutical compositions comprising it and its use | EGIS Gyógyszergyár Nyilvánosan Müködõ Részvénytársaság (HU) | 2008-12-03 | — | — | EP | claimed |
| EP-1963335-A2 | PROCESS FOR THE PREPARATION OF OLANZAPINE | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2008-09-03 | — | — | EP | claimed |
| WO-2007054750-A2 | PROCESS FOR THE PREPARATION OF OLANZAPINE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2007-05-18 | — | — | WO | claimed |
| US-7981884-B2 | Process for the preparation of olanzapine | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2011-07-19 | — | — | US | disclosed |
| US-7981884-B2 | Process for the preparation of olanzapine | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2011-07-19 | — | — | US | disclosed |
| EP-1963335-B1 | PROCESS FOR THE PREPARATION OF OLANZAPINE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKOEDOE RESZVENYTARSASAG (HU) | 2011-05-04 | — | — | EP | disclosed |
| US-20090137563-A1 | PROCESS FOR THE PREPARTION OF OLANZAPINE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-05-28 | — | — | US | disclosed |
| US-20090137563-A1 | PROCESS FOR THE PREPARTION OF OLANZAPINE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2009-05-28 | — | — | US | disclosed |
| CN-101400683-A | Process for the preparation of olanzapine | EGIS GYOGYSZERGYAR NYILVANOSAN (HU) | 2009-04-01 | — | — | CN | disclosed |
| EP-1997822-A1 | Process for the preparation of 2-methyl-4-(4-methylpiperazin-1-yl)-10h-thieno-[2,3-b] [1,5] benzodiazepine dihydrochloride trihydrate, 2-methyl-4-(4-methyl-piperazin-1-yl) -10h-thieno[2,3-b] [1,5] benzodiazepine dihydrochloride trihydrate, pharmaceutical compositions comprising it and its use | EGIS Gyógyszergyár Nyilvánosan Müködõ Részvénytársaság (HU) | 2008-12-03 | — | — | EP | disclosed |
| EP-1997822-A1 | Process for the preparation of 2-methyl-4-(4-methylpiperazin-1-yl)-10h-thieno-[2,3-b] [1,5] benzodiazepine dihydrochloride trihydrate, 2-methyl-4-(4-methyl-piperazin-1-yl) -10h-thieno[2,3-b] [1,5] benzodiazepine dihydrochloride trihydrate, pharmaceutical compositions comprising it and its use | EGIS Gyógyszergyár Nyilvánosan Müködõ Részvénytársaság (HU) | 2008-12-03 | — | — | EP | disclosed |
| EP-1963335-A2 | PROCESS FOR THE PREPARATION OF OLANZAPINE | Egis Gyógyszergyár Nyilvánosan Múködö Részvénytársaság (HU) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007054750-A2 | PROCESS FOR THE PREPARATION OF OLANZAPINE | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137563-A1 | PROCESS FOR THE PREPARTION OF OLANZAPINE | HTR1B, CYP3A5, HTR5A | DRD2 50/4885HTR2A 26/4885HTR2C 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.